Comparative Pharmacology
Head-to-head clinical analysis: HEXABRIX versus ISOVUE 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXABRIX versus ISOVUE 250.
HEXABRIX vs ISOVUE-250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby providing contrast enhancement in imaging studies. Its mechanism of action is physical rather than pharmacological, as it does not have inherent biological activity.
Intravenous: 0.3-0.6 mL/kg (maximum 100 mL) for urography; 40-80 mL for CT enhancement.
Intravenous administration of 50-150 mL (12-37 g iodine) for CT imaging; intra-arterial administration of 10-80 mL (2.5-20 g iodine) for angiography; dose depends on procedure and patient weight.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in adults (prolonged in renal impairment; up to 30 hours in severe CKD)
Terminal elimination half-life: 1.5-2 hours (normal renal function); clinically, half-life prolonged in renal impairment
Renal: 95% unchanged via glomerular filtration; Biliary: <5%; Fecal: <1%
Primarily renal: 90-95% unchanged in urine within 24 hours; biliary/fecal: <5%
Category C
Category C
Contrast Media
Contrast Media